Compare Cassava Sciences Inc (FLNA) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vital Farms Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Vital Farms Inc trades at $9.45 (market cap $405.27M). The key difference: Vital Farms Inc is far larger — about 10.3× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 1,810,837). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Vital Farms Inc for 14 Days on average.
| FLNA | VITL | |
|---|---|---|
Market Cap | $39.40M | $405.27M |
Volume | 759,018 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $43.68 |
52-Week Low | $0.68 | $8.28 |
Typical Hold Time | 37 Days | 14 Days |
Enterprise Value | -$43.28M | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Vital Farms (VITL) trades at $9.24, down 1.7% on the day, reflecting ongoing pressure from weak earnings and industry headwinds. The stock shows a bearish technical trend with key support at $9.00, while fundamentals reveal a sharp decline in profitability with a net margin of just 0.02% in 2026. Recent news highlights strategic review discussions and institutional acquisitions, yet negative cash flow and pricing challenges in the egg market weigh on investor confidence.
The outlook remains cautious with significant execution risks amid industry oversupply, though analyst consensus suggests upside potential to a $13.11 price target. Investment opportunity hinges on a successful strategic review and margin recovery, but risks include sustained cash burn and competitive pressures that could limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
